Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898806 · ClinicalTrials.gov registry record · Phase 4
Intralesional Steroids in the Treatment of Alopecia Areata
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01898806: Clinical Trial Phase 4 study, sponsored by Columbia University.
NCT01898806 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01898806, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months, nonresponders or partial responders may be treated for 6 months with open label triamcinolone at the dose deemed appropriate by the investigator. The investigators will also perform skin biopsies of the scalp and draw blood at selected time points in order to examine the immunohistochemical/pathological response in scalp hair follicles and the systemic circulation to treatment with IL TAC for alopecia areata.
Primary Outcome
Comparison of the proportion of responders in each group, with response defined as 50% change (% change NOT absolute change) in SALT score from baseline (50% regrowth at week 24).
Interventions
- DRUG Intralesional Triamcinolone 10 mg/ml
- DRUG Intralesional Triamcinolone 2.5 mg/ml
- DRUG Intralesional Triamcinolone 5 mg/ml
- DRUG Intralesional Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-09 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Why NCT01898806 stopped before completion
NCT01898806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Intralesional Triamcinolone 10 mg/ml is the first listed.
NCT01898806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01898806 about?
NCT01898806 is a clinical study titled "Intralesional Steroids in the Treatment of Alopecia Areata". This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months, nonresponders or pa...
What is the current status of trial NCT01898806?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2011-09. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01898806?
The interventions under investigation include: Intralesional Triamcinolone 10 mg/ml (DRUG), Intralesional Triamcinolone 2.5 mg/ml (DRUG), Intralesional Triamcinolone 5 mg/ml (DRUG), Intralesional Saline (DRUG).
Who is sponsoring clinical trial NCT01898806?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01898806's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia